Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain

April 11, 2021 updated by: Annette C. Toledano MD

A Proof-of-Concept, Randomized, Double-Blind and Placebo Controlled Clinical Trial With Naltrexone and Clonidine Combination (ATNC05) Compared With Placebo in the Treatment of Chronic Back Pain

The study includes back pain of the cervical, thoracic, and the lumbar regions.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

78

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Florida
      • North Miami, Florida, United States, 33181
        • Annette C. Toledano MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

The subject has chronic back pain for > 3 months in the lumbar, thoracic or cervical regions.

The average pain intensity scale during the screening week is 4/10 - 8/10 (On an 11-point Numeric Pain Intensity Scale with 0 = no pain and 10 = worst pain imaginable).

The subject has not taken Opioid medications 7 days prior to initiation of study drug.

The subject has a heart rate of 60bpm or above and/or systolic blood pressure 90 or above.

The subject is willing to refrain from using NSAIDS, Acetaminophen or muscle relaxants, unless for rescue, for the duration of the study The subject is willing to refrain from using Opioid medications and excessive alcohol for the duration of the study.

The subject is able to read, understand and follow the study instructions, including completion of questionnaires at home.

The subject must sign an informed consent document indicating willingness to participate.

If the subject is a female, she must be post-menopausal, not currently pregnant or nursing. A female of child bearing potential should be using a reliable contraception method during the course of the study.

Exclusion Criteria:

The subject has a positive urine drug screen. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.

The subject has any significant deviations from normal in physical examination, electrocardiogram (ECG), Echocardiogram or clinical laboratory tests, as evaluated by the investigator.

The subject has a history of an allergic reaction to the components of the study drug.

The subject has acute back or cervical pain. The subject has muscular back or cervical pain. The subject has back or cervical pain other than chronic Radicular pain.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: placebo
Drug: placebo
subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
Experimental: ATNC05 - a study drug capsule
Naltrexone and Clonidine Combination (ATNC05)
Drug: Naltrexone and Clonidine Combination
subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
Other Names:
  • ATNC05

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in Brief Pain Inventory 24-hour Pain Scores for average pain (Question #5)
Time Frame: baseline to week 3
The Brief Pain Inventory is a self-reported medical questionnaire used to measure pain over the past 24-hours - worst pain (Question 3), least pain (Question 4), average pain (Question 5), right now pain (Question 6) and at night pain (Question 7). The score ranges from 0 to 10 (0 - no pain) (10 - intolerable pain).
baseline to week 3

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in Brief Pain Inventory 24-hour assessment of interference in function (Questions 9a - 9i).
Time Frame: baseline to week 1, week 2 and week 3
BPI Interference; questions 9a - 9i - measures a self-reported assessment of the interference in function because of pain in past 24 hours in general activity, mood, walking ability, normal work, relationship with other people, sleep quality, enjoyment of life, standing ability and sitting ability. Interference scores: 0 (does not interfere) to 10 (completely interferes).
baseline to week 1, week 2 and week 3
Change From Baseline in Brief Pain Inventory 24-hour subject's Global Impression of Improvement (Question 8)
Time Frame: baseline to week 1, week 2 and week 3
The Brief Pain Inventory question 8 measures the subject's perception of how much relief he has received at the time of assessment compared with before the start of the study drug. The score is measured in percentage 0% (no relief) to100% (complete relief).
baseline to week 1, week 2 and week 3
Change From Baseline in the subject's Global Assessment of Treatment Satisfaction today
Time Frame: baseline to week 1, week 2 and week 3
A self-reported scale that measures Treatment Satisfaction today in (0-10, 0 - none, 10 - most satisfied)
baseline to week 1, week 2 and week 3
Change from Baseline in the subject's perception of Ability to Tolerate the study drug and the severity of side effects today.
Time Frame: baseline to week 1, week 2 and week 3
A self-reported scale that measures the ability to tolerate the study drug and the severity of side effects today in (0-10, 0 - No side effects, 10 - intolerable side effects)
baseline to week 1, week 2 and week 3
Change From Baseline in Oswestry Disability Index and Neck Disability composite scores(ODI), to Week 1, Week 2, and Week 3
Time Frame: baseline to week 1, week 2 and week 3
The Oswestry Low Back Pain Disability Questionnaire (Oswestry Disability Index) and Neck Disability composite assesses pain-related disability in persons with low back pain (LBP) and neck pain. The score is recorded in percentage of disability.
baseline to week 1, week 2 and week 3
Change From Baseline in Roland Morris Disability Questionnaire composite scores(ODI), to Week 1, Week 2, and Week 3
Time Frame: baseline to week 1, week 2 and week 3
The Roland Morris Disability Questionnaire consists of 24 statements and the subject is instructed to put a mark next to each appropriate statement. The total score ranges from 0 (no disability) to 24 (severe disability).
baseline to week 1, week 2 and week 3
Change From Baseline in Vital Signs - systolic blood pressure, diastolic blood pressure, pulse rate and body mass index to Week 1, Week 2, and Week 3.
Time Frame: baseline to week 1, week 2 and week 3
baseline to week 1, week 2 and week 3
Change from Baseline to week 3 in Laboratory Assessments - Alkaline Phosphatase, Alanine Transaminase - ALT (SGPT), Aspartate transaminase - AST(SGOT), Bilirubin, Total, Serum Creatinine, Blood Urea Nitrogen, Serum Chloride, Potassium, HCO3
Time Frame: baseline to week 1, week 2 and week 3
baseline to week 1, week 2 and week 3
Change from Baseline in the investigator's Clinical Global Impression - Severity scale (CGI-S) to Week 1, Week 2, week 3 .
Time Frame: baseline to week 1, week 2 and week 3
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the investigator to rate the severity of the subject's back pain at the time of assessment, relative to the investigator's past experience. Considering total clinical experience, the subject is assessed on severity of back pain at the time of rating 1, normal; 2, borderline; 3, mild; 4, moderate; 5, marked; 6, severe; or 7, extreme.
baseline to week 1, week 2 and week 3
Change from Baseline in The investigator's Clinical Global Impression - Improvement scale (CGI-I) to Week 1, Week 2, week 3
Time Frame: baseline to week 1, week 2 and week 3
The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale, the investigator will rate how much the patient's back pain has improved or worsened relative to a baseline state at the beginning of the study and rate as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
baseline to week 1, week 2 and week 3
Change from Baseline in the subject's answer to the question, "Are you better off today then the time before starting the study drug?, yes/no, by what percentage?
Time Frame: baseline to week 1, week 2 and week 3
Answer, yes/no and by 0%-100% (0%-not at all better, 100% - very much better off
baseline to week 1, week 2 and week 3
Change From Baseline in the subject's answer to the question " Have you been more / less active in the past 24 hrs, comparing to the period before initiating the study drug, please rate in %.
Time Frame: baseline to week 1, week 2 and week 3
The subjects answer, one of the following choices, - 150%, -100%, -50%, - 25%, 0% - same activity level, +25%, +50%, +100%, +150%
baseline to week 1, week 2 and week 3
Subject's response to the question, "Have you responded to the treatment?"
Time Frame: baseline to week 1, week 2 and week 3
Subject's answer yes/no.
baseline to week 1, week 2 and week 3
Subject's Global Assessment of Disease Activity Improved / No Change
Time Frame: baseline to week 1, week 2 and week 3
The Subject answer either Improved or No Change.
baseline to week 1, week 2 and week 3
Subject's Global Evaluation of Study Medication.
Time Frame: baseline to week 1, week 2 and week 3
The subject chooses, 1 - Excellent, 2 - Very Good, 3 - Good, 4 - Fair, 5 - Poor
baseline to week 1, week 2 and week 3
The Subject's Satisfaction with Pain Relief, 0 - 10.
Time Frame: baseline to week 1, week 2 and week 3
The subject answers on a scale of 0-10, (0 - not satisfied, 10 - very satisfied).
baseline to week 1, week 2 and week 3
The Subject's Satisfaction with Moving, Standing, Walking and Bending Ability Scale, 0-10.
Time Frame: baseline to week 1, week 2 and week 3.
The subjects answers on a scale of 0-10, (0 - not satisfied, 10 - very satisfied)
baseline to week 1, week 2 and week 3.
Change from Baseline in Brief Pain Inventory 24-hour Pain Scores for worst pain, least pain, right now pain and night pain (Questions 3,4,6 & 7)
Time Frame: baseline to week 1, week 2 and week 3
The Brief Pain Inventory is a self-reported medical questionnaire used to measure pain over the past 24-hours - worst pain (Question 3), least pain (Question 4), average pain (Question 5), right now pain (Question 6) and at night pain (Question 7). The score ranges from 0 to 10 (0 - no pain) (10 - intolerable pain).
baseline to week 1, week 2 and week 3

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Annette C. Toledano MD

Investigators

  • Principal Investigator: Annette C Toledano, MD, Allodynic Therapeutics, LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2011

Primary Completion (Actual)

February 1, 2013

Study Completion (Actual)

February 1, 2013

Study Registration Dates

First Submitted

August 11, 2011

First Submitted That Met QC Criteria

August 11, 2011

First Posted (Estimate)

August 12, 2011

Study Record Updates

Last Update Posted (Actual)

April 14, 2021

Last Update Submitted That Met QC Criteria

April 11, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AT110491

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lower Back Pain

Clinical Trials on Naltrexone and Clonidine Combination

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe